Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Snyder Mark Drugs Roselle, Inc. d.b.a. Mark Drugs Pharmacy
483
•Snyder Mark Drugs Roselle, Inc. d.b.a. Mark Drugs Pharmacy•September 27, 2019

Snyder Mark Drugs Roselle, Inc. d.b.a. Mark Drugs Pharmacy – FDA 483, Sep 27, 2019

Record Details

The FDA conducted an inspection of Snyder Mark Drugs Roselle, Inc., operating as Mark Drugs Pharmacy, from September 16 to September 27, 2019. This inspection identified significant deficiencies in the firm's production of sterile and non-sterile drug products, indicating a lack of adherence to current Good Manufacturing Practices. Key observations included the failure to certify ISO 5 aseptic processing areas under dynamic conditions, specifically lacking smoke studies to demonstrate unidirectional airflow during simulated production. Investigators also noted the use of non-sterile wipes within these critical ISO 5 aseptic processing environments. Furthermore, the firm's media fill simulations, designed to evaluate aseptic processes, did not adequately represent worst-case conditions, maximum activities, or the full complement of personnel involved in operations, thus failing to sufficiently challenge aseptic procedures. Most critically, the inspection revealed a complete absence of endotoxin testing for intrathecal drug products and their non-sterile starting materials, providing no assurance of safety regarding endotoxin levels in these high-risk preparations. These observations highlight fundamental control issues that could compromise drug sterility and patient safety. Mark Drugs Pharmacy is required to promptly address these concerns, implementing comprehensive corrective actions to ensure compliance with regulatory standards and safeguard public health.

Company
Snyder Mark Drugs Roselle, Inc. d.b.a. Mark Drugs Pharmacy
Inspection date
September 27, 2019
Product type
Drugs
Office
Minneapolis District Office
People
  • Anthony J. Ladner (Pharmacist at U.S. Public Health Service Commissioned Corps)
  • Norman K. Starks
View Company Profile

ID · 35e096ff-dfdb-4c95-b43b-e90c32c1126a

Violation Codes3
21 U.S.C. 331(c)21 CFR 21021 CFR 211

Full citation text and observation details available on the Dashboard.

Other documents for Snyder Mark Drugs Roselle, Inc. d.b.a. Mark Drugs Pharmacy
  • WARNING_LETTER - 2017-05-22May 22, 2017

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Snyder Mark Drugs Roselle, Inc. d.b.a. Mark Drugs Pharmacy
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.